This site is intended for healthcare professionals

NMPA accepts sBLA in China for tislelizumab to treat esophageal squamous cell carcinoma- BeiGene Ltd.

Read time: 1 mins
Last updated:29th Jul 2021
Published:8th Jul 2021
BeiGene, Ltd. announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental Biologics License Application (sBLA) for anti-PD1 antibody tislelizumab for the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have disease progression following or are intolerant to first-line standard chemotherapy.
Condition: Oesophageal Cancer
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest